<DOC>
	<DOCNO>NCT00265122</DOCNO>
	<brief_summary>The purpose study examine safety efficacy CNTO 1275 participant active Crohn 's Disease .</brief_summary>
	<brief_title>A Study Safety Efficacy Ustekinumab ( CNTO 1275 ) Participants With Crohn 's Disease</brief_title>
	<detailed_description>This multicenter , randomize study IL-12p40 ( CNTO 1275 ) , hereafter refer ustekinumab , 2 population participant moderately severely active Crohn 's disease least 6 week duration . A total approximately 120 volunteer participate study Canada , Belgium , United States . Two separate group participant ( Population 1 Population 2 ) evaluate . The primary population participant ( Population 1 ) consist approximately 100 participant Crohn 's disease despite treatment standard Crohn 's disease medication ( include agent decrease intestinal inflammation 5-ASA medication PENTASA , ASACOL ) , corticosteroids prednisone and/or drug know suppress immune system call immunomodulators azathioprine , 6-mercaptopurine , methotrexate , infliximab adalimumab [ market trade name HUMMIRA ] ) . Participants Population 1 randomly assign ( assigned chance , like `` flip coin '' ) double-blind treatment ( participant study staff know identity treatment ) ustekinumab placebo ( inactive substance ) 1 4 treatment group follow : ( 1 ) 4 week treatment ustekinumab 90 mg follow 4 week treatment placebo inject subcutaneously ( SC , skin ) , ( II ) 4 week placebo follow 4 week ustekinumab 90 mg inject SC , ( III ) 1 intravenous ( IV , vein ) infusion ustekinumab 4.5 mg/kg follow 1 IV infusion placebo , ( IV ) 1 IV infusion placebo follow 1 IV infusion ustekinumab 4.5 mg/kg . Population 2 consist approximately 20 participant fail respond previous therapy infliximab ( trade name REMICADE ) , type antibody decrease inflammation patient moderate severe Crohn 's disease ) . All participant Population 2 receive open-label ( un-blinded ) treatment ustekinumab 4.5 mg/kg administer SC 4 week one IV infusion . Placebo give participant Population 2 . The duration study participant 28 week ( include screen period 2 week ) participant return Week 54 blood sample collect assess concentration ustekinumab antibody ustekinumab . Adverse event ( side-effects ) measure safety tolerability result routine laboratory test monitor report throughout study time inform consent document 3 day final blood sample collection Week 54 . Note : dos ustekinumab use study adjust factor 0.9 consistent correct absorptivity constant ustekinumab . Therefore , ustekinumab dose 100 mg 5 mg/kg previously state study protocol restate 90 mg 4.5 mg/kg , respectively . No change make amount ustekinumab give participant study .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have moderately severly active Crohn 's disease fistulizing Crohn 's disease least 6 week ' duration Crohn 's disease activity index ( CDAI ) score &gt; =220 &lt; =450 In Population 1 , participant must active disease despite treatment 5ASA compound , antibiotic , corticosteroid , and/or immunomodulators , include antiTNF agent . In Population 2 , participant must active disease fail respond infliximab maximum approve dose treatment regimen Crohn 's disease define US package insert . Have local manifestation Crohn 's disease stricture , abscess , disease complication surgery might indicate Had intraabdominal surgery within 6 month prior enter study Have receive treatment parenteral nutrition ( ie , introduction nutrition body via route mouth ) ( total parenteral nutrition [ TPN ] ) within 6 week baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Crohn Disease</keyword>
	<keyword>Biologic</keyword>
	<keyword>Infusion</keyword>
	<keyword>Injection</keyword>
	<keyword>CNTO 1275</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>C01275</keyword>
	<keyword>IL-12p40</keyword>
</DOC>